Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

R1402

Raloxifene hydrochloride

selective estrogen receptor modulator (SERM), solid

Synonyme(s) :

Keoxifene hydrochloride, LY 156758, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C28H27NO4S · HCl
Numéro CAS:
82640-04-8
Poids moléculaire :
510.04
UNSPSC Code:
51111800
PubChem Substance ID:
24278673
NACRES:
NA.77
MDL number:
MFCD01938233
Form:
solid
Quality level:
100
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Raloxifene hydrochloride, solid

form

solid

Quality Level

100

color

light yellow

solubility

DMSO: soluble 28 mg/mL, H2O: insoluble

originator

Eli Lilly

SMILES string

Cl[H].Oc1ccc(cc1)-c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4

InChI

1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H

InChI key

BKXVVCILCIUCLG-UHFFFAOYSA-N

Gene Information

human ... ESR2(2100)

Application

Raloxifene hydrochloride has been used:
  • as a competitive inhibitors for estrogen receptor α in breast cancer cells
  • as an anti-resorptive agents to test its effect on improving bone mineral density (BMD) in six-month-old female ovariectomized rats
  • to test effect on viability of esophageal adenocarcinoma cells

Biochem/physiol Actions

Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.
Raloxifene is benzothiophene compound and is used in treating postmenopausal osteoporosis It comparatively induces lesser risk in developing thromboembolic events and cataracts compared to tamoxifen. Raloxifene also interacts with estrogen receptors and plasma proteins.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under

pictograms

Health hazard
GHS08

signalword

Warning

Hazard Classifications

Carc. 2 - Repr. 2

Classe de stockage

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
MKCT9972
MKCS3577
MKCJ7180
MKCH5566
MKCD0733

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Contenu apparenté

Raloxifene
Moen MD, et al.
Drugs (2008)
Rachel K Surowiec et al.
Bone, 173, 116805-116805 (2023-05-18)
Raloxifene (RAL) reduces clinical fracture risk despite modest effects on bone mass and density. This reduction in fracture risk may be due to improved material level-mechanical properties through a non-cell mediated increase in bone hydration. Synthetic salmon calcitonin (CAL) has
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
Fanning SW, et al.
eLife, 7, e37161-e37161 (2018)
Afficher tous les articles scientifiques apparentés